Emergent BioSolutions (EBS) Tops Q1 EPS by 41c; Guides Q2 Revs Lower
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.70 -3.89%
Financial Fact:
Weighted-average number of shares - diluted: 49.44M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Weighted-average number of shares - diluted: 49.44M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $1.53, $0.41 better than the analyst estimate of $1.12. Revenue for the quarter came in at $343 million versus the consensus estimate of $358.47 million.
GUIDANCE:
Emergent BioSolutions sees Q2 2021 revenue of $370-430 million, versus the consensus of $502.3 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
- Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
- Etsy upgraded to buy at BofA on durable growth, buyback potential
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
